XML 19 R10.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues | 3 Months Ended
--- | ---
Mar. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions):
|  | Three months ended March 31,
|  | 2019 |  | 2018
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,106 |  |  | $ | 45 |  |  | $ | 1,151 |  |  | $ | 1,050 |  |  | $ | 55 |  |  | $ | 1,105 |
Neulasta® (pegfilgrastim) |  | 893 |  |  | 128 |  |  | 1,021 |  |  | 1,009 |  |  | 146 |  |  | 1,155 |
Prolia® (denosumab) |  | 390 |  |  | 202 |  |  | 592 |  |  | 320 |  |  | 174 |  |  | 494 |
XGEVA® (denosumab) |  | 356 |  |  | 115 |  |  | 471 |  |  | 332 |  |  | 113 |  |  | 445 |
Aranesp® (darbepoetin alfa) |  | 182 |  |  | 232 |  |  | 414 |  |  | 225 |  |  | 229 |  |  | 454 |
KYPROLIS® (carfilzomib) |  | 154 |  |  | 91 |  |  | 245 |  |  | 137 |  |  | 85 |  |  | 222 |
EPOGEN® (epoetin alfa) |  | 219 |  |  | — |  |  | 219 |  |  | 244 |  |  | — |  |  | 244 |
Sensipar®/Mimpara® (cinacalcet) |  | 135 |  |  | 78 |  |  | 213 |  |  | 409 |  |  | 88 |  |  | 497 |
Other products |  | 556 |  |  | 404 |  |  | 960 |  |  | 421 |  |  | 306 |  |  | 727 |
Total product sales(1) |  | $ | 3,991 |  |  | $ | 1,295 |  |  | 5,286 |  |  | $ | 4,147 |  |  | $ | 1,196 |  |  | 5,343 |
Other revenues |  |  |  |  |  | 271 |  |  |  |  |  |  | 211 |
Total revenues |  |  |  |  |  | $ | 5,557 |  |  |  |  |  |  | $ | 5,554 |
____________
(1) | Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2019 and 2018.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration